- TheStreet.com•36 minutes ago
An Amgen drug to treat secondary hyperparathyroidism was rejected by U.S. regulators Wednesday but the biotech company offered no public explanation for why the drug's marketing application was denied....
- 24/7 Wall St.•1 hour ago
The August 15 short interest data have been compared with the previous report, and short interest moves were mixed across these selected biotech stocks.
Amgen Inc. (AMGN)
NasdaqGS - NasdaqGS Real Time Price. Currency in USD
|Bid||169.67 x 100|
|Ask||169.84 x 100|
|Day's Range||169.08 - 170.63|
|52wk Range||130.09 - 176.64|
|1y Target Est||N/A|
Trade prices are not sourced from all markets
|P/E Ratio (ttm)||17.45|
|Avg Vol (3m)||2,872,682|
|Dividend & Yield||4.00 (2.29%)|